Sanford-Burnham, Pfizer Team in Hunt for Insulin Resistance Targets | GenomeWeb

NEW YORK (GenomeWeb News) – The Sanford-Burnham Medical Research Institute said today that its investigators will collaborate with Pfizer to identify therapeutic targets for use in preventing and treating complications related to obesity and diabetes.

Under the three-year collaboration, the partners at Pfizer and Sanford-Burnham's Conrad Prebys Center for Chemical Genomics will use novel screening tools and systems biology approaches to develop treatment methods for reducing insulin resistance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.